En pacientes adultos que toman corticoides, que tan efectivo es el uso de bisfosfonatos en comparacion con el uso solo de calcio.?

P: Pacientes adultos que toman corticoides para enferemedades reumáticas

I: Bisfosfonatos

C: Calcio

O: Osteoporosis, fractura

Artículos Propuestos

Proponente Referencia Ver/Descargar
Alex Casallas Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z. Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. PloS one. 2013;8(12):e80890.
Yimy Medina Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2003;18(5):919-24.
Jorge Abella Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. 2009,Lancet 373, 1253–1263
Renan Morales Amy Warriner, MD1 and Kenneth G Saag, MD MSc2 . Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids . Curr Osteoporos Rep. 2013 December ; 11(4): 341–347.
Javier Atuesta Chan YH, Soo S, Tan S, Yu I, Tsou Y, Tan SH, et al. Prevention of Glucocorticoid-Induced Osteoporosis in Immunobullous Diseases With Alendronate. 2013;148(3):307–14.
Carolina Jimenez Boutsen, Y., Jamart, J., Esselinckx, W. and Devogelaer, J. P. Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1-Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone. J Bone Miner Res, 2001. 16: 104–112.
Carmenza Liliana Sandoval Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202–11.
Eybar Díaz Hakala, M., Kröger, H., Valleala, H., Hienonen-Kempas, T., Lehtonen-Veromaa, M., Heikkinen, J., ... & Paimela, L. (2012). Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scandinavian journal of rheumatology41(4), 260-266.

Puntos clave/Conclusiones